Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Common Equity (2016 - 2025)

Historic Common Equity for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $161.5 million.

  • Regenxbio's Common Equity fell 4643.55% to $161.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.5 million, marking a year-over-year decrease of 4643.55%. This contributed to the annual value of $259.7 million for FY2024, which is 1670.97% down from last year.
  • As of Q3 2025, Regenxbio's Common Equity stood at $161.5 million, which was down 4643.55% from $213.7 million recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Common Equity registered a high of $764.3 million during Q4 2021, and its lowest value of $161.5 million during Q3 2025.
  • Over the past 5 years, Regenxbio's median Common Equity value was $405.9 million (recorded in 2023), while the average stood at $430.7 million.
  • In the last 5 years, Regenxbio's Common Equity soared by 10232.74% in 2021 and then plummeted by 4643.55% in 2025.
  • Regenxbio's Common Equity (Quarter) stood at $764.3 million in 2021, then plummeted by 32.46% to $516.2 million in 2022, then plummeted by 39.61% to $311.7 million in 2023, then fell by 16.71% to $259.7 million in 2024, then plummeted by 37.82% to $161.5 million in 2025.
  • Its last three reported values are $161.5 million in Q3 2025, $213.7 million for Q2 2025, and $274.2 million during Q1 2025.